Frontiers in pulmonary hypertension in infants and children with bronchopulmonary dysplasia

Pediatric Pulmonology

Volumn 47, Issue 11, 2012, Pages 1042-1053

  Collaco, Joseph M ^a   Romer, Lewis H ^a   Stuart, Bridget D ^a   Coulson, John D ^a   Everett, Allen D ^a   Lawson, Edward E ^a   Brenner, Joel I ^a   Brown, Anna T ^a   Nies, Melanie K ^a   Sekar, Priya ^a   Nogee, Lawrence M ^a   McGrath Morrow, Sharon A ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

bronchopulmonary dysplasia; chronic lung disease; prematurity; pulmonary hypertension

Indexed keywords

BOSENTAN; BRAIN NATRIURETIC PEPTIDE; BRONCHODILATING AGENT; CORTICOSTEROID; DIPEPTIDYL CARBOXYPEPTIDASE; DIURETIC AGENT; ILOPROST; MANNOSE BINDING LECTIN; MILRINONE; NITRIC OXIDE; PROSTACYCLIN; SILDENAFIL; SURFACTANT PROTEIN B; SURFACTANT PROTEIN D; TOLL LIKE RECEPTOR 5; TRANSCRIPTION FACTOR NRF2; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; BIRTH WEIGHT; BREATHING EXERCISE; CELL GROWTH; CELL MIGRATION; CELL PROLIFERATION; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; DISEASE ASSOCIATION; DISEASE SEVERITY; ECHOCARDIOGRAPHY; ENVIRONMENTAL FACTOR; EPIGENETICS; EXTRACORPOREAL OXYGENATION; GENE EXPRESSION; GENETIC ASSOCIATION; HEALTH CARE COST; HEART CATHETERIZATION; HEART SEPTUM DEFECT; HOSPITALIZATION; HUMAN; IMMUNOPROPHYLAXIS; LOSS OF FUNCTION MUTATION; LUNG ARTERY PRESSURE; LUNG BLOOD VESSEL; LUNG DYSPLASIA; LUNG RESISTANCE; LUNG TRANSPLANTATION; LUNG VENTILATION PERFUSION RATIO; MOLECULAR PATHOLOGY; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; POSITIVE END EXPIRATORY PRESSURE; PREMATURITY; PRIORITY JOURNAL; PULMONARY HYPERTENSION; QUALITY OF LIFE; SINGLE NUCLEOTIDE POLYMORPHISM; SMALL FOR DATE INFANT; SYSTOLIC BLOOD PRESSURE; THORAX RADIOGRAPHY;

ANESTHESIA; BIOLOGICAL MARKERS; BRONCHOPULMONARY DYSPLASIA; CARDIAC CATHETERIZATION; CHILD; CHILD, PRESCHOOL; ECHOCARDIOGRAPHY; HUMANS; HYPERTENSION, PULMONARY; INCIDENCE; INFANT; INFANT, NEWBORN; PREVALENCE; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 84867741972     PISSN: 87556863     EISSN: 10990496     Source Type: Journal    
DOI: 10.1002/ppul.22609     Document Type: Article

References (93)

1. Viscardi RM,. Perinatal inflammation and lung injury. Semin Fetal Neonatal Med 2012; 17: 30-35.
2. Kallapur SG, Jobe AH,. Contribution of inflammation to lung injury and development. Arch Dis Child Fetal Neonatal Ed 2006; 91: F132-F135.
3. Ehrenkranz RA, Walsh MC, Vohr BR, Jobe AH, Wright LL, Fanaroff AA, Wrage LA, Poole K,. Validation of the national institutes of health consensus definition of bronchopulmonary dysplasia. Pediatrics 2005; 116: 1353-1360.
4. Gough A, Spence D, Linden M, Halliday HL, McGarvey L,. General and respiratory health outcomes in adult survivors of bronchopulmonary dysplasia: a systematic review. Chest 2012; 141: 1554-1567.
5. Kim DH, Kim HS, Choi CW, Kim EK, Kim BI, Choi JH,. Risk factors for pulmonary artery hypertension in preterm infants with moderate or severe bronchopulmonary dysplasia. Neonatology 2012; 101: 40-46.
6. An HS, Bae EJ, Kim GB, Kwon BS, Beak JS, Kim EK, Kim HS, Choi JH, Noh CI, Yun YS,. Pulmonary hypertension in preterm infants with bronchopulmonary dysplasia. Korean Circ J 2010; 40: 131-136.
7. Khemani E, McElhinney DB, Rhein L, Andrade O, Lacro RV, Thomas KC, Mullen MP,. Pulmonary artery hypertension in formerly premature infants with bronchopulmonary dysplasia: clinical features and outcomes in the surfactant era. Pediatrics 2007; 120: 1260-1269.
8. Kumar VH, Hutchison AA, Lakshminrusimha S, Morin FC III, Wynn RJ, Ryan RM,. Characteristics of pulmonary hypertension in preterm neonates. J Perinatol 2007; 27: 214-219.
9. Slaughter JL, Pakrashi T, Jones DE, South AP, Shah TA,. Echocardiographic detection of pulmonary hypertension in extremely low birth weight infants with bronchopulmonary dysplasia requiring prolonged positive pressure ventilation. J Perinatol 2011; 31: 635-640.
10. Bhat R, Salas AA, Foster C, Carlo WA, Ambalavanan N,. Prospective analysis of pulmonary hypertension in extremely low birth weight infants. Pediatrics 2012; 129: e682-e689.
11. Farquhar M, Fitzgerald DA,. Pulmonary hypertension in chronic neonatal lung disease. Paediatr Respir Rev 2010; 11: 149-153.
12. Berger RM, Beghetti M, Humpl T, Raskob GE, Ivy DD, Jing ZC, Bonnet D, Schulze-Neick I, Barst RJ,. Clinical features of paediatric pulmonary hypertension: a registry study. Lancet 2012; 379: 537-546.
13. Cerro MJ, Abman S, Diaz G, Freudenthal AH, Freudenthal F, Harikrishnan S, Haworth SG, Ivy D, Lopes AA, Raj JU, et al. A consensus approach to the classification of pediatric pulmonary hypertensive vascular disease: report from the PVRI pediatric taskforce, Panama 2011. Pulm Circ 2011; 1: 286-298.
14. Lapaire O, Shennan A, Stepan H,. The preeclampsia biomarkers soluble fms-like tyrosine kinase-1 and placental growth factor: current knowledge, clinical implications and future application. Eur J Obstet Gynecol Reprod Biol 2010; 151: 122-129.
15. Tang JR, Karumanchi SA, Seedorf G, Markham N, Abman SH,. Excess soluble vascular endothelial growth factor receptor-1 in amniotic fluid impairs lung growth in rats: linking preeclampsia with bronchopulmonary dysplasia. Am J Physiol Lung Cell Mol Physiol 2012; 302: L36-L46.
16. Li F, Hagaman JR, Kim HS, Maeda N, Jennette JC, Faber JE, Karumanchi SA, Smithies O, Takahashi N,. eNOS deficiency acts through endothelin to aggravate sFlt-1-induced pre-eclampsia-like phenotype. J Am Soc Nephrol 2012; 23: 652-660.
17. Kim GB,. Pulmonary hypertension in infants with bronchopulmonary dysplasia. Korean J Pediatr 2010; 53: 688-693.
18. Mourani PM, Mullen M, Abman SH,. Pulmonary hypertension in bronchopulmonary dysplasia. Progress in Pediatric Cardiology 2009; 27: 43-48.
19. Barst RJ,. Classification of pediatric pulmonary hypertensive vascular disease: does it need to be different from the adult classification? Pulm Circ 2011; 1: 134-137.
20. Abman SH, Ivy DD,. Recent progress in understanding pediatric pulmonary hypertension. Curr Opin Pediatr 2011; 23: 298-304.
21. Lum S, Kirkby J, Welsh L, Marlow N, Hennessy E, Stocks J,. Nature and severity of lung function abnormalities in extremely pre-term children at 11 years of age. Eur Respir J 2011; 37: 1199-1207.
22. Baraldi E, Carraro S, Filippone M,. Bronchopulmonary dysplasia: definitions and long-term respiratory outcome. Early Hum Dev 2009; 85: S1-S3.
23. Northway WH Jr, Moss RB, Carlisle KB, Parker BR, Popp RL, Pitlick PT, Eichler I, Lamm RL, Brown BW Jr., Late pulmonary sequelae of bronchopulmonary dysplasia. N Engl J Med 1990; 323: 1793-1799.
24. Yee M, White RJ, Awad HA, Bates WA, McGrath-Morrow SA, O'Reilly MA,. Neonatal hyperoxia causes pulmonary vascular disease and shortens life span in aging mice. Am J Pathol 2011; 178: 2601-2610.
25. Jobe AH,. Blood cytokines and BPD. J Pediatr 2009; 154: A2.
26. Speer CP,. New insights into the pathogenesis of pulmonary inflammation in preterm infants. Biol Neonate 2001; 79: 205-209.
27. Speer CP,. Inflammation and bronchopulmonary dysplasia. Semin Neonatol 2003; 8: 29-38.
28. Speer CP,. Pulmonary inflammation and bronchopulmonary dysplasia. J Perinatol 2006; 26: S57-S62.
29. Bagchi A, Viscardi RM, Taciak V, Ensor JE, McCrea KA, Hasday JD,. Increased activity of interleukin-6 but not tumor necrosis factor-alpha in lung lavage of premature infants is associated with the development of bronchopulmonary dysplasia. Pediatr Res 1994; 36: 244-252.
30. Case J, Ingram DA, Haneline LS,. Oxidative stress impairs endothelial progenitor cell function. Antioxid Redox Signal 2008; 10: 1895-1907.
31. Lee JW, Davis JM,. Future applications of antioxidants in premature infants. Curr Opin Pediatr 2011; 23: 161-166.
32. McGrath-Morrow S, Lauer T, Yee M, Neptune E, Podowski M, Thimmulappa RK, O'Reilly M, Biswal S,. Nrf2 increases survival and attenuates alveolar growth inhibition in neonatal mice exposed to hyperoxia. Am J Physiol Lung Cell Mol Physiol 2009; 296: L565-L573.
33. Balasubramaniam V, Maxey AM, Fouty BW, Abman SH,. Nitric oxide augments fetal pulmonary artery endothelial cell angiogenesis in vitro. Am J Physiol Lung Cell Mol Physiol 2006; 290: L1111-L1116.
34. Askie LM, Ballard RA, Cutter GR, Dani C, Elbourne D, Field D, Hascoet JM, Hibbs AM, Kinsella JP, Mercier JC, et al. Inhaled nitric oxide in preterm infants: an individual-patient data meta-analysis of randomized trials. Pediatrics 2011; 128: 729-739.
35. Donohue PK, Gilmore MM, Cristofalo E, Wilson RF, Weiner JZ, Lau BD, Robinson KA, Allen MC,. Inhaled nitric oxide in preterm infants: a systematic review. Pediatrics 2011; 127: e414-e422.
36. Ryoo S, Lemmon CA, Soucy KG, Gupta G, White AR, Nyhan D, Shoukas A, Romer LH, Berkowitz DE,. Oxidized low-density lipoprotein-dependent endothelial arginase II activation contributes to impaired nitric oxide signaling. Circ Res 2006; 99: 951-960.
37. Vadivel A, Aschner JL, Rey-Parra GJ, Magarik J, Zeng H, Summar M, Eaton F, Thébaud B,. L-citrulline attenuates arrested alveolar growth and pulmonary hypertension in oxygen-induced lung injury in newborn rats. Pediatr Res 2010; 68: 519-525.
38. Bhandari V, Bizzarro MJ, Shetty A, Zhong X, Page GP, Zhang H, Ment LR, Gruen JR, Neonatal Genetics Study Group. Familial and genetic susceptibility to major neonatal morbidities in preterm twins. Pediatrics 2006; 117: 1901-1906.
39. Lavoie PM, Pham C, Jang KL,. Heritability of bronchopulmonary dysplasia, defined according to the consensus statement of the national institutes of health. Pediatrics 2008; 122: 479-485.
40. Ryckman KK, Dagle JM, Kelsey K, Momany AM, Murray JC,. Genetic associations of surfactant protein D and angiotensin-converting enzyme with lung disease in preterm neonates. J Perinatol 2011; 32: 349-355.
41. Sampath V, Garland JS, Le M, Patel AL, Konduri GG, Cohen JD, Simpson PM, Hines RN,. A TLR5 (g.1174C>T) variant that encodes a stop codon (R392X) is associated with bronchopulmonary dysplasia. Pediatr Pulmonol 2011; 117: 1901-1906.
42. Hadchouel A, Durrmeyer X, Bouzigon E, Incitti R, Huusko J, Jarreau PH, Lenclen R, Demenais F, Franco-Montoya ML, Layouni I, et al. Identification of SPOCK2 as a susceptibility gene for bronchopulmonary dysplasia. Am J Respir Crit Care Med 2011; 184: 1164-1170.
43. Koukoura O, Sifakis S, Spandidos DA,. DNA methylation in the human placenta and fetal growth (Review). Mol Med Report 2012; 5: 883-889.
44. Li M, Riddle SR, Frid MG, El Kasmi KC, McKinsey TA, Sokol RJ, Strassheim D, Meyrick B, Yeager ME, Flockton AR, et al. Emergence of fibroblasts with a proinflammatory epigenetically altered phenotype in severe hypoxic pulmonary hypertension. J Immunol 2011; 187: 2711-2722.
45. Dhillon R,. The management of neonatal pulmonary hypertension. Arch Dis Child Fetal Neonatal Ed 2012; 97: F223-F228.
46. Currie PJ, Seward JB, Chan KL, Fyfe DA, Hagler DJ, Mair DD, Reeder GS, Nishimura RA, Tajik AJ,. Continuous wave Doppler determination of right ventricular pressure: a simultaneous Doppler-catheterization study in 127 patients. J Am Coll Cardiol 1985; 6: 750-756.
47. Hill KD, Lim DS, Everett AD, Ivy DD, Moore JD,. Assessment of pulmonary hypertension in the pediatric catheterization laboratory: current insights from the magic registry. Catheter Cardiovasc Interv 2010; 76: 865-873.
48. Mourani PM, Sontag MK, Younoszai A, Ivy DD, Abman SH,. Clinical utility of echocardiography for the diagnosis and management of pulmonary vascular disease in young children with chronic lung disease. Pediatrics 2008; 121: 317-325.
49. Drossner DM, Kim DW, Maher KO, Mahle WT,. Pulmonary vein stenosis: prematurity and associated conditions. Pediatrics 2008; 122: e656-e661.
50. Mullen MP,. Diagnostic strategies for acute presentation of pulmonary hypertension in children: particular focus on use of echocardiography, cardiac catheterization, magnetic resonance imaging, chest computed tomography, and lung biopsy. Pediatr Crit Care Med 2010; 11: S23-S26.
51. Barst RJ, McGoon MD, Elliott CG, Foreman AJ, Miller DP, Ivy DD,. Survival in childhood pulmonary arterial hypertension: insights from the registry to evaluate early and long-term pulmonary arterial hypertension disease management. Circulation 2012; 125: 113-122.
52. Mourani PM, Mullen M, Abman SH,. Pulmonary hypertension in bronchopulmonary dysplasia. Prog Pediatr Cardiol 2009; 27: 43-48.
53. Taylor CJ, Derrick G, McEwan A, Haworth SG, Sury MR,. Risk of cardiac catheterization under anaesthesia in children with pulmonary hypertension. Br J Anaesth 2007; 98: 657-661.
54. Lorenzen JM, Nickel N, Kramer R, Golpon H, Westerkamp V, Olsson KM, Haller H, Hoeper MM,. Osteopontin in patients with idiopathic pulmonary hypertension. Chest 2011; 139: 1010-1017.
55. Goto K, Arai M, Watanabe A, Hasegawa A, Nakano A, Kurabayashi M,. Utility of echocardiography versus BNP level for the prediction of pulmonary arterial pressure in patients with pulmonary arterial hypertension. Int Heart J 2010; 51: 343-347.
56. Andreassen AK, Wergeland R, Simonsen S, Geiran O, Guevara C, Ueland T,. N-terminal pro-B-type natriuretic peptide as an indicator of disease severity in a heterogeneous group of patients with chronic precapillary pulmonary hypertension. Am J Cardiol 2006; 98: 525-529.
57. Mauritz GJ, Rizopoulos D, Groepenhoff H, Tiede H, Felix J, Eilers P, Bosboom J, Postmus PE, Westerhof N, Vonk-Noordegraaf A,. Usefulness of serial N-terminal pro-B-type natriuretic peptide measurements for determining prognosis in patients with pulmonary arterial hypertension. Am J Cardiol 2011; 108: 1645-1650.
58. Nir A, Lindinger A, Rauh M, Bar-Oz B, Laer S, Schwachtgen L, Koch A, Falkenberg J, Mir TS,. NT-pro-B-type natriuretic peptide in infants and children: reference values based on combined data from four studies. Pediatr Cardiol 2009; 30: 3-8.
59. Albers S, Mir TS, Haddad M, Laer S,. N-Terminal pro-brain natriuretic peptide: normal ranges in the pediatric population including method comparison and interlaboratory variability. Clin Chem Lab Med 2006; 44: 80-85.
60. Joseph L, Nir A, Hammerman C, Goldberg S, Ben SE, Picard E,. N-terminal pro-B-type natriuretic peptide as a marker of bronchopulmonary dysplasia in premature infants. Am J Perinatol 2010; 27: 381-386.
61. McGrath-Morrow SA, Ryan T, McGinley BM, Okelo SO, Sterni LM, Collaco JM,. Polysomnography in preterm infants and children with chronic lung disease. Pediatr Pulmonol 2012; 47: 172-179.
62. Mourani PM, Sontag MK, Ivy DD, Abman SH,. Effects of long-term sildenafil treatment for pulmonary hypertension in infants with chronic lung disease. J Pediatr 2009; 154: 379-384.
63. Nyp M, Sandritter T, Poppinga N, Simon C, Truog WE,. Sildenafil citrate, bronchopulmonary dysplasia and disordered pulmonary gas exchange: any benefits? J Perinatol 2012; 32: 64-69.
64. Farrow KN, Steinhorn RH,. Phosphodiesterases: emerging therapeutic targets for neonatal pulmonary hypertension. Handb Exp Pharmacol 2011; 204: 251-277.
65. Caputo S, Furcolo G, Rabuano R, Basilicata AM, Pilla LM, De Simone A, Pasquariello B, Ciampi Q, Vetrano G, Villari B,. Severe pulmonary arterial hypertension in a very premature baby with bronchopulmonary dysplasia: normalization with long-term sildenafil. J Cardiovasc Med (Hagerstown) 2010; 11: 704-706.
66. Hon KL, Cheung KL, Siu KL, Leung TF, Yam MC, Fok TF, Ng PC,. Oral sildenafil for treatment of severe pulmonary hypertension in an infant. Biol Neonate 2005; 88: 109-112.
67. Abman SH,. Monitoring cardiovascular function in infants with chronic lung disease of prematurity. Arch Dis Child Fetal Neonatal Ed 2002; 87: F15-F18.
68. Bell SG,. Bosentan. Neonatal Netw 2011; 30: 249-251.
69. Eifinger F, Sreeram N, Mehler K, Huenseler C, Kribs A, Roth B,. Aerosolized iloprost in the treatment of pulmonary hypertension in extremely preterm infants: a pilot study. Klin Padiatr 2008; 220: 66-69.
70. Gurakan B, Kayiran P, Ozturk N, Kayiran SM, Dindar A,. Therapeutic combination of sildenafil and iloprost in a preterm neonate with pulmonary hypertension. Pediatr Pulmonol 2011; 46: 617-620.
71. Hwang SK, YC O, Kim NS, Park HK, Yum MK,. Use of inhaled iloprost in an infant with bronchopulmonary dysplasia and pulmonary artery hypertension. Korean Circ J 2009; 39: 343-345.
72. Krishnan U, Krishnan S, Gewitz M,. Treatment of pulmonary hypertension in children with chronic lung disease with newer oral therapies. Pediatr Cardiol 2008; 29: 1082-1086.
73. Radicioni M, Bruni A, Camerini P,. Combination therapy for life-threatening pulmonary hypertension in a premature infant: first report on bosentan use. Eur J Pediatr 2011; 170: 1075-1078.
74. Rosati E, Butera G, Bossone E, De FC, Latini G,. Inhaled nitric oxide and oral nifedipine in a preterm infant with bronchopulmonary dysplasia and pulmonary hypertension. Eur J Pediatr 2007; 166: 737-738.
75. Zaidi AN, Dettorre MD, Ceneviva GD, Thomas NJ,. Epoprostenol and home mechanical ventilation for pulmonary hypertension associated with chronic lung disease. Pediatr Pulmonol 2005; 40: 265-269.
76. Lederman HM, Metz SJ, Zuckerberg AL, Loughlin GM,. Antibody deficiency complicating severe bronchopulmonary dysplasia. Pediatr Pulmonol 1989; 7: 52-54.
77. Benden C, Aurora P, Edwards LB, Kucheryavaya AY, Christie JD, Dobbels F, Kirk R, Rahmel AO, Stehlik J, Hertz MI,. the registry of the international society for heart and lung transplantation: fourteenth pediatric lung and heart-lung transplantation report-2011. J Heart Lung Transplant 2011; 30: 1123-1132.
78. Luong C, Rey-Perra J, Vadivel A, Gilmour G, Sauve Y, Koonen D, Walker D, Todd KG, Gressens P, Kassiri Z, et al. Antenatal sildenafil treatment attenuates pulmonary hypertension in experimental congenital diaphragmatic hernia. Circulation 2011; 123: 2120-2131.
79. Carmosino MJ, Friesen RH, Doran A, Ivy DD,. Perioperative complications in children with pulmonary hypertension undergoing noncardiac surgery or cardiac catheterization. Anesth Analg 2007; 104: 521-527.
80. Friesen RH, Williams GD,. Anesthetic management of children with pulmonary arterial hypertension. Paediatr Anaesth 2008; 18: 208-216.
81. Diaz LK, Jones L,. Sedating the child with congenital heart disease. Anesthesiol Clin 2009; 27: 301-319.
82. Tobias JD, Gupta P, Naguib A, Yates AR,. Dexmedetomidine: applications for the pediatric patient with congenital heart disease. Pediatr Cardiol 2011; 32: 1075-1087.
83. Brown AT, Gillespie JV, Miquel-Verges F, Holmes K, Ravekes W, Spevak P, Brady K, Easley RB, Golden WC, McNamara L, et al. Inhaled epoprostenol therapy for pulmonary hypertension: improves oxygenation index more consistently in neonates than in older children. Pulmonary Circulation 2012; 2: 61-66.
84. Piastra M, De LD, De Carolis MP, Tempera A, Stival E, Caliandro F, Pietrini D, Conti G, De Rosa G,. Nebulized iloprost and noninvasive respiratory support for impending hypoxaemic respiratory failure in formerly preterm infants: a case series. Pediatr Pulmonol 2011; DOI: 10.1002/ppul.21619.
85. Ivy DD, Doran AK, Smith KJ, Mallory GB Jr, Beghetti M, Barst RJ, Brady D, Law Y, Parker D, Claussen L, et al. Short- and long-term effects of inhaled iloprost therapy in children with pulmonary arterial hypertension. J Am Coll Cardiol 2008; 51: 161-169.
86. Humbert M, Barst RJ, Robbins IM, Channick RN, Galiè N, Boonstra A, Rubin LJ, Horn EM, Manes A, Simonneau G,. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J 2004; 24: 353-359.
87. Mohamed WA, Ismail M,. A randomized, double-blind, placebo-controlled, prospective study of bosentan for the treatment of persistent pulmonary hypertension of the newborn. J Perinatol 2011; DOI: 10.1038/jp.2011.
88. Francis SH, Busch JL, Corbin JD, Sibley D,. cGMP-dependent protein kinases and cGMP phosphodiesterases in nitric oxide and cGMP action. Pharmacol Rev 2010; 62: 525-563.
89. Sehgal A, Athikarisamy SE, Adamopoulos M,. Global myocardial function is compromised in infants with pulmonary hypertension. Acta Paediatr 2012; 101: 410-413.
90. Shukla AC, Almodovar MC,. Anesthesia considerations for children with pulmonary hypertension. Pediatr Crit Care Med 2010; 11: S70-S73.
91. van der Griend BF, Lister NA, McKenzie IM, Martin N, Ragg PG, Sheppard SJ, Davidson AJ,. Postoperative mortality in children after 101,885 anesthetics at a tertiary pediatric hospital. Anesth Analg 2011; 112: 1440-1447.
92. Morray JP, Geiduschek JM, Ramamoorthy C, Haberkern CM, Hackel A, Caplan RA, Domino KB, Posner K, Cheney FW,. Anesthesia-related cardiac arrest in children: initial findings of the pediatric perioperative cardiac arrest (POCA) registry. Anesthesiology 2000; 93: 6-14.
93. Gorenflo M, Gu H, Xu Z,. Peri-operative pulmonary hypertension in paediatric patients: current strategies in children with congenital heart disease. Cardiology 2010; 116: 10-17.